Randomized trial of olmesartan and azelnidipine for treatment of hypertension with chronic kidney disease

Randomized trial of olmesartan and azelnidipine for treatment of hypertension with chronic kidney disease - Best Combination Therapy in Juntendo(BECOME-J)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006920

Enrollment

100

Registered

2011-12-20

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension with CKD

Interventions

Ormesartan 40mg Ormesartan 20mg plus Azelnidipine16mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 1) who have treated with ormesartan 20mg alone for more than 1 month 2)whose systolic BP>125mmHg and/or diastolic BP 75mmHg 3) with macro- or micro-albuminuria

Exclusion criteria

Exclusion criteria: 1)secondary hypertension 2)patients who used to have side effects by ormesartan and/or azelnidipine 3)pregnacy 4)with steroid therapy 5)malignancy 6)severe liver disease

Design outcomes

Primary

Measure	Time frame
albuminuria blood pressure eGFR	—

Secondary

Measure	Time frame
Urinary angiotensinogen excresion serum ADMA	—

Countries

Japan

Contacts

Public ContactSatoshi Horikoshi

Juntendo University Nephrology

satoshi@juntendo.ac.jp03-5802-1065

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026